Brexit in Healthcare Report
There is much uncertainty as to what the UK healthcare industry will look like after Brexit.
More than half of participants we interviewed agreed that the UK would take at least three years for its healthcare industry to stabilize in the event of a “No Deal” Brexit. Currently the pharmaceutical industry is a leading sector of wealth, with a growth value added to the UK economy of £13.8M ($21.7M*) in 2016. GlaxoSmithKline and AstraZeneca are UK-headquartered and generated combined global sales of over $61B in 2018 alone. The UK also has sizeable operations from leading multinational companies such as Pfizer, Roche, Novartis, and Johnson & Johnson (J&J).
It has been over three years since the UK voted to leave the EU. As Brexit deadlines loom, negotiations are still ongoing to determine the UK’s relationship with the EU after Brexit.
Our Brexit in Healthcare report series provides in-house analyst expertise on the results of a survey of GlobalData Pharma clients and prospects. Participants answered questions about how they expect Brexit to affect healthcare, both from within and outside of the UK.
